[Paper Review] Umbilical Cord Blood Banking and its Therapeutic Uses

Nivethika Sivakumaran, Imesha Rashmini Rathnayaka+6 more|arXiv (Cornell University)|Feb 21, 2018

Mesenchymal stem cell research21 references3 citations

TL;DR

This paper reviews umbilical cord blood (UCB) banking as a promising source of hematopoietic stem cells with low collection cost and high therapeutic potential. It highlights UCB's immunological immaturity, plasticity, and multipotency in treating malignant and nonmalignant disorders, with cord blood banking enabling long-term storage for clinical use.

ABSTRACT

Umbilical cord blood (UBC) can be viewed as the most promising source of stem cells, in which collection cost is minimal and its benefits are immense. The cord blood is used to treat malignant and nonmalignant diseases; this is due to its progenitor characteristics know as stem cells.Its properties of being, immunologically immature and high plasticity has made it superior to other sources of stem cells. The stem cells collected from cord blood have neutral differentiation capabilities which allow medical professionals to produce functional neural cells from these stem cells.Cord Blood Banking (CBB) is the storing of the umbilical cord blood which is collected immediately after the delivery of the baby. Great care and concern are needed for proper storage of these progenitor cells, hence cord blood banks come into the play, they are of 3 types which are: public, private and direct donation banks.Clinical trials are still at its very early stages having abundances to still be uncovered but results were obtained have demonstrated high potential and more scope towards effective development therapies and treatments for rare disorders.

Motivation & Objective

• To evaluate the therapeutic potential of umbilical cord blood (UCB) as a source of stem cells for treating various diseases.
• To examine the role of cord blood banking in preserving hematopoietic stem cells for future medical use.
• To assess the advantages of UCB over other stem cell sources, including low immunogenicity and high plasticity.
• To explore current clinical applications and future prospects of UCB in regenerative medicine.
• To compare different cord blood banking models—public, private, and direct donation—based on accessibility and clinical utility.

Proposed method

• Systematic review of existing literature on umbilical cord blood banking and its clinical applications.
• Analysis of stem cell properties in UCB, including self-renewal, multipotency, and immunomodulatory potential.
• Classification and description of three types of cord blood banks: public, private, and direct donation.
• Evaluation of preclinical and clinical trial data on UCB-derived stem cells in treating malignant and nonmalignant diseases.
• Discussion of technical and logistical challenges in UCB collection, processing, and long-term storage.
• Assessment of emerging research on neural differentiation potential of UCB stem cells.

Experimental results

Research questions

• RQ1 What are the key biological properties of umbilical cord blood stem cells that make them suitable for regenerative medicine?
• RQ2 How do public, private, and direct donation cord blood banking models differ in terms of accessibility and clinical application?
• RQ3 What are the current clinical indications for umbilical cord blood transplantation?
• RQ4 To what extent do preclinical studies support the use of UCB stem cells in treating neurological disorders?
• RQ5 What are the remaining challenges and future research directions in umbilical cord blood banking and therapy?

Key findings

• Umbilical cord blood is a rich source of hematopoietic stem cells with high proliferative and multilineage differentiation potential.
• The immunological immaturity of UCB stem cells reduces the risk of graft-versus-host disease, enhancing transplant safety.
• Cord blood banking enables long-term preservation of stem cells, supporting future autologous or allogeneic use.
• Clinical trials have demonstrated promising outcomes in treating hematological malignancies, inherited metabolic disorders, and certain neurological conditions.
• The plasticity and neutral differentiation capacity of UCB stem cells allow for the generation of functional neural cells in vitro.
• Despite early-stage clinical trials, UCB therapy shows significant potential for treating rare and currently incurable disorders.